Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

What symbol and exchange does Nasus Pharma Ltd. shares trade?

Nasus Pharma Ltd. trades on the AMEX stock market under the symbol NSRX.

What is Nasus Pharma Ltd. stock price doing today?

As of October 30, 2026, NSRX stock price declined to $3.07 with 4,888 million shares trading.

What is Nasus Pharma Ltd.'s Beta?

NSRX has a beta of 1.82, meaning it tends to be more sensitive to market movements. NSRX has a correlation of 0.05 to the broad based SPY ETF.

How much is Nasus Pharma Ltd. worth?

NSRX has a market cap of $35.95 million. This is considered a Sub-Micro Cap stock.

Is Nasus Pharma Ltd. (NSRX) a good investment?

NSRX has underperformed the market in the last year with a price return of -60.5% while the SPY ETF gained +12.3%. NSRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.5% and -3.5%, respectively, while the SPY returned +2.1% and -1.0%, respectively.

What are the support and resistance levels for Nasus Pharma Ltd. (NSRX)?

NSRX support price is $2.97 and resistance is $3.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NSRX shares will trade within this expected range on the day.